Evidence map›Paper›PMID 39180315›Full record

ArticleThe journal of histochemistry and cytochemistry : official journal of the Histochemistry Society

Histone Acetyl Transferase 1 Is Overexpressed in Poor Prognosis, High-grade Meningeal and Glial Brain Cancers: Immunohistochemical and Aptahistochemical Study.

Sandra Bargiela-Cuevas, María Marin, María Gabaldon-Ojeda, José I Klett-Mingo, Paula Granado, Silvia Sacristan, Alfonso Esteban-Lasso, José G Casas, María E Martin, Victor M M González and 4 more

Abstract read
In one paragraph

Article in The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sandra Bargiela-CuevasCell Biology and Genetics, Department of Biomedicine and Biotechnology, University of Alcalá, Alcalá de Henares, Spain.
María MarinLaboratory Medicine Department, Hospital Central de la Defensa Gómez Ulla, Madrid, Spain.
María Gabaldon-OjedaCell Biology and Genetics, Department of Biomedicine and Biotechnology, University of Alcalá, Alcalá de Henares, Spain.
José I Klett-MingoCentro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.ORCID 0000-0002-5467-1892
Paula GranadoCell Biology and Genetics, Department of Biomedicine and Biotechnology, University of Alcalá, Alcalá de Henares, Spain.
Silvia SacristanAptamer Group, Department Biochemistry-Research, Ramón y Cajal Institute of Sanitary Research, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Alfonso Esteban-LassoInari Biotech, S.L., Madrid, Spain.
José G CasasEORTC, Medical Department, Bruxelles, Belgium (JGC).ORCID 0000-0001-6962-8697
María E MartinAptamer Group, Department Biochemistry-Research, Ramón y Cajal Institute of Sanitary Research, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Victor M M GonzálezAptamer Group, Department Biochemistry-Research, Ramón y Cajal Institute of Sanitary Research, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Mar RoyuelaCell Biology and Genetics, Department of Biomedicine and Biotechnology, University of Alcalá, Alcalá de Henares, Spain.ORCID 0000-0003-1999-9849
Ignacio García-TuñonCell Biology and Genetics, Department of Biomedicine and Biotechnology, University of Alcalá, Alcalá de Henares, Spain.ORCID 0000-0003-4758-2151
Miguel Angel Ortega NúñezDepartment of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, Alcalá de Henares, Spain.
María Del Val Toledo LoboCell Biology and Genetics, Department of Biomedicine and Biotechnology, University of Alcalá, Alcalá de Henares, Spain.ORCID 0000-0001-7222-8096

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary malignancies of the central nervous system account for 2% of all cancers in adults and almost 15% in children under 15 years of age. The prognosis of brain anaplastic cancers and glioblastomas remains extremely poor, with devastating survival expectative, and new molecular markers and therapeutic targets are essential. Epigenetic changes constitute an extensive field for the development of new diagnostic and therapeutic strategies. Histone acetyl transferase-1 (HAT1) has merged as a potential prognostic marker and therapy target for different malignancies. Data repository analysis showed HAT1 mRNA overexpression in gliomas and has been described its alternative splicing in glioblastomas. Using immunohistochemical and aptahistochemical methods, we analyzed the expression of HAT1 in meningiomas, oligodendrogliomas, and astroglial cancers. We observed that HAT1 overexpression is associated with the most aggressive tumor types and the worse prognosis, as well as with a higher probability of early relapse in meningiomas. Its cytosolic localization correlates with tumor progression and prognosis. Aptamers, synthetic oligonucleotides capable to bind and inhibit a wide variety of targets, are considered as promising diagnostic and therapeutic tools. Aptahistochemistry using the aptamer apHAT610 offered superior results in comparison with the antibody used, as a good example of the potential of aptamers as diagnostic tools for histopathology.

Indexed as

Brain NeoplasmsHistone AcetyltransferasesImmunohistochemistryMeningeal NeoplasmsAdultAgedBiomarkers, TumorFemaleGliomaHumansMaleMeningiomaMiddle AgedNeoplasm GradingPrognosisBiomarkers, TumorHistone Acetyltransferaseshistone acetyltransferase type B complexaptahistochemistryglioblastomaHAT1immunohistochemistrymeningiomaoligodendroglioma

Identifiers

PMID39180315
PMCPMC11423361

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.